{"corpus_id":22826405,"paper_sha":"55137face5215ab80d79e577d83c1d1481c976c9","doi":"10.1503/cmaj.081041","arxiv_id":null,"pmid":19221352,"pmcid":"PMC2638025","mag_id":2132584445,"dblp_id":null,"acl_id":null,"title":"Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis","year":2009,"publication_date":"2009-02-17","venue":"Canadian Medical Association Journal","journal":{"name":"Canadian Medical Association Journal","pages":"385 - 397","volume":"180"},"journal_issn":null,"journal_title":null,"publication_types":["MetaAnalysis","JournalArticle","Review"],"pubmed_pub_types":["Journal Article","Meta-Analysis","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine"],"reference_count":152,"citation_count":243,"influential_citation_count":11,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Diabetes Mellitus","mj":false,"qs":[{"q":"drug therapy","mj":true,"ui":"Q000188"}],"ui":"D003920"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Hypoglycemic Agents","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D007004"},{"d":"Insulin","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"analogs & derivatives","mj":true,"ui":"Q000031"},{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D007328"},{"d":"Randomized Controlled Trials as Topic","mj":false,"ui":"D016032"}],"chemicals":[{"n":"Hypoglycemic Agents","ui":"D007004","reg":"0"},{"n":"Insulin","ui":"D007328","reg":"0"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://www.cmaj.ca/content/cmaj/180/4/385.full.pdf","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/55137face5215ab80d79e577d83c1d1481c976c9","s2_open_access_license":"CCBYNCND","s2_open_access_status":"GOLD","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Background: Although insulin analogues are commonly prescribed for the management of diabetes mellitus, there is uncertainty regarding their optimal use. We conducted meta-analyses to compare the outcomes of insulin analogues with conventional insulins in the treatment of type 1, type 2 and gestational diabetes. Methods: We updated 2 earlier systematic reviews of the efficacy and safety of rapid-and long-acting insulin analogues. We searched electronic databases, conference proceedings and “grey literature” up to April 2007 to identify randomized controlled trials that compared insulin analogues with conventional insulins. Study populations of interest were people with type 1 and type 2 diabetes (adult and pediatric) and women with gestational diabetes. Results: We included 68 randomized controlled trials in the analysis of rapid-acting insulin analogues and 49 in the analysis of long-acting insulin analogues. Most of the studies were of short to medium duration and of low quality. In terms of hemoglobin A1c, we found minimal differences between rapid-acting insulin analogues and regular human insulin in adults with type 1 diabetes (weighted mean difference for insulin lispro: –0.09%, 95% confidence interval [CI] –0.16% to –0.02%; for insulin aspart: –0.13%, 95% CI –0.20% to –0.07%). We observed similar outcomes among patients with type 2 diabetes (weighted mean difference for insulin lispro: –0.03%, 95% CI –0.12% to –0.06%; for insulin aspart: –0.09%, 95% CI –0.21% to 0.04%). Differences between long-acting insulin analogues and neutral protamine Hagedorn insulin in terms of hemoglobin A1c were marginal among adults with type 1 diabetes (weighted mean difference for insulin glargine: –0.11%, 95% CI –0.21% to –0.02%; for insulin detemir: –0.06%, 95% CI –0.13% to 0.02%) and among adults with type 2 diabetes (weighted mean difference for insulin glargine: –0.05%, 95% CI –0.13% to 0.04%; for insulin detemir: 0.13%, 95% CI 0.03% to 0.22%). Benefits in terms of reduced hypoglycemia were inconsistent. There were insufficient data to determine whether insulin analogues are better than conventional insulins in reducing long-term diabetes-related complications or death. Interpretation: Rapid-and long-acting insulin analogues offer little benefit relative to conventional insulins in terms of glycemic control or reduced hypoglycemia. Long-term, high-quality studies are needed to determine whether insulin analogues reduce the risk of long-term complications of diabetes.","claims":[{"public_id":"cl_a79f2a838d92dbff4b669300cd4e47f6","status":"active","text":"Available data were insufficient to determine whether insulin analogues reduce long-term diabetes-related complications or death.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_a79f2a838d92dbff4b669300cd4e47f6"},{"public_id":"cl_bb14378ec76fe74f723ead100142bc7b","status":"active","text":"Long-acting insulin analogues showed only marginal hemoglobin A1c differences compared with neutral protamine Hagedorn insulin in adults with type 1 diabetes and type 2 diabetes.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_bb14378ec76fe74f723ead100142bc7b"},{"public_id":"cl_8f400c1e42ba5005724bb3c43dc2c82e","status":"active","text":"Rapid-acting and long-acting insulin analogues offer little benefit over conventional insulins for glycemic control or reduction of hypoglycemia.","confidence":0.99,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_8f400c1e42ba5005724bb3c43dc2c82e"},{"public_id":"cl_4a8fd30732c3f7d15b4bfde2b03972c5","status":"active","text":"Rapid-acting insulin analogues produced only minimal hemoglobin A1c differences compared with regular human insulin in adults with type 1 diabetes.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_4a8fd30732c3f7d15b4bfde2b03972c5"},{"public_id":"cl_2d30e06c32753ce11efeac7be03415dc","status":"active","text":"Rapid-acting insulin analogues showed similarly small hemoglobin A1c differences compared with regular human insulin in type 2 diabetes.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_2d30e06c32753ce11efeac7be03415dc"},{"public_id":"cl_4310f3cbe488af75cdd323de6a542b03","status":"active","text":"Reductions in hypoglycemia with insulin analogues were inconsistent.","confidence":0.93,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_4310f3cbe488af75cdd323de6a542b03"}],"concepts":[{"public_id":"co_0fac6e6add5de3b18e826342b794f423","status":"active","name":"insulin analogues","description":"Modified insulin preparations used to manage diabetes mellitus.","types":["treatment"],"aliases":["insulin analogs"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_0fac6e6add5de3b18e826342b794f423"},{"public_id":"co_1239da7d221e8cd03b9e2c268618cea6","status":"active","name":"rapid-acting insulin analogues","description":"Insulin analogues designed for fast onset of glucose-lowering action around meals.","types":["treatment"],"aliases":["rapid-acting insulin analogs"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_1239da7d221e8cd03b9e2c268618cea6"},{"public_id":"co_19347eeeff6590ea6b14e923f1d47df9","status":"active","name":"long-term diabetes-related complications","description":"Chronic complications associated with diabetes, such as vascular or organ damage.","types":["outcome"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_19347eeeff6590ea6b14e923f1d47df9"},{"public_id":"co_2f08e9e81da7c89f711793e0bffe0096","status":"active","name":"regular human insulin","description":"A short-acting human insulin preparation used as a comparator for rapid-acting insulin analogues.","types":["treatment"],"aliases":["regular insulin"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_2f08e9e81da7c89f711793e0bffe0096"},{"public_id":"co_56152cb821e1353d3a006bbf75a9c5ef","status":"active","name":"neutral protamine Hagedorn insulin","description":"An intermediate-acting human insulin preparation used as a comparator for long-acting insulin analogues.","types":["treatment"],"aliases":["NPH insulin"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_56152cb821e1353d3a006bbf75a9c5ef"},{"public_id":"co_5d01b25468f876f2bcbd0b7d8485072d","status":"active","name":"conventional insulins","description":"Standard human insulin preparations used as comparators in the meta-analysis.","types":["treatment"],"aliases":["conventional insulin"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_5d01b25468f876f2bcbd0b7d8485072d"},{"public_id":"co_634ec08f81ef188ac490156292c2ffda","status":"active","name":"hypoglycemia","description":"Episodes of abnormally low blood glucose.","types":["outcome"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_634ec08f81ef188ac490156292c2ffda"},{"public_id":"co_a726c2e4d4086450155d1d167212d97c","status":"active","name":"type 2 diabetes","description":"A form of diabetes characterized by insulin resistance and relative insulin deficiency.","types":["condition"],"aliases":["T2D"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a726c2e4d4086450155d1d167212d97c"},{"public_id":"co_b2910c3e2393810fdc0f23a47c720b22","status":"active","name":"hemoglobin A1c","description":"A blood biomarker reflecting average long-term glycemic control.","types":["outcome"],"aliases":["HbA1c"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b2910c3e2393810fdc0f23a47c720b22"},{"public_id":"co_b77be867d043b496165e8287da25b48e","status":"active","name":"type 1 diabetes","description":"A form of diabetes characterized by insulin deficiency and the need for insulin treatment.","types":["condition"],"aliases":["T1D"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b77be867d043b496165e8287da25b48e"},{"public_id":"co_cc23b33f233697d3bed333bf37fca23a","status":"active","name":"long-acting insulin analogues","description":"Insulin analogues designed to provide prolonged basal insulin coverage.","types":["treatment"],"aliases":["long-acting insulin analogs"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_cc23b33f233697d3bed333bf37fca23a"},{"public_id":"co_e02630a744b736d23023eafc9802bbf3","status":"active","name":"death","description":"All-cause mortality assessed as a clinical outcome.","types":["outcome"],"aliases":["mortality"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_e02630a744b736d23023eafc9802bbf3"}],"external_ids":{"DOI":"10.1503/cmaj.081041","ArXiv":null,"PubMed":19221352,"PubMedCentral":"PMC2638025","MAG":2132584445,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://www.cmaj.ca/content/cmaj/180/4/385.full.pdf","landing_url":"https://www.semanticscholar.org/paper/55137face5215ab80d79e577d83c1d1481c976c9","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBYNCND","status":"GOLD","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":632238,"paper_uid":"bd8fc374-5c39-4ca8-ab0d-f5bf3243cf88","canonical_identity":{"paper_id":632238,"paper_uid":"bd8fc374-5c39-4ca8-ab0d-f5bf3243cf88","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/22826405"}